Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M MutationGeoffrey R. Oxnard, Vincent A. Miller, Maria E. Arcila et al.|Clinical Cancer Research|2010Cited by 624
Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with <i>EGFR</i>-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib: Implications for Clinical Trial DesignJamie E. Chaft, Gregory J. Riely, Geoffrey R. Oxnard et al.|Clinical Cancer Research|2011Cited by 421
Prognostic Impact of KRAS Mutation Subtypes in 677 Patients with Metastatic Lung AdenocarcinomasHelena A. Yu, Gregory J. Riely, Camelia S. Sima et al.|Journal of Thoracic Oncology|2014Cited by 138
Smoking History and Response to Nivolumab in Patients with Advanced NsclcsMatthew D. Hellmann, Naiyer A. Rizvi, Ben Creelan et al.|Annals of Oncology|2014Cited by 32